Fürstenau, M., Giza, A., Weiss, J., Kleinert, F., Robrecht, S., Franzen, F., . . . Cramer, P. (2024). Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL: Final efficacy and ctDNA analysis of the CLL2-BAAG trial. Blood, 144(3), . https://doi.org/10.1182/blood.2023022730
Chicago-Zitierstil (17. Ausg.)Fürstenau, Moritz, et al. "Acalabrutinib, Venetoclax, and Obinutuzumab in Relapsed/refractory CLL: Final Efficacy and CtDNA Analysis of the CLL2-BAAG Trial." Blood 144, no. 3 (2024). https://doi.org/10.1182/blood.2023022730.
MLA-Zitierstil (9. Ausg.)Fürstenau, Moritz, et al. "Acalabrutinib, Venetoclax, and Obinutuzumab in Relapsed/refractory CLL: Final Efficacy and CtDNA Analysis of the CLL2-BAAG Trial." Blood, vol. 144, no. 3, 2024, https://doi.org/10.1182/blood.2023022730.